_id
69105a28ccc777a4e85d578b
Ticker
DERM
Name
Journey Medical Corp
Exchange
NASDAQ
Address
9237 East Via de Ventura Boulevard, Scottsdale, AZ, United States, 85258
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://journeymedicalcorp.com
Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Last Close
7.78
Volume
85095
Current Price
7.68
Change
-1.2853470437018062
Last Updated
2025-11-29T12:11:37.961Z
Image
data:image/webp;base64,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
Ipo Date
2021-11-12T00:00:00.000Z
Market Cap
218986736
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.99175
Sentiment Sources
4
Rating
4.75
Target Price
13.5
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
17631000
Cost Of Revenue
5755000
Gross Profit
11876000
Operating Expenses
13405000
Operating Income
-1529000
Interest Expense
937000
Pretax Income
-2315000
Net Income
-2315000
Eps
-0.09275168982360511
Dividends Per Share
-
Shares Outstanding
21135905
Income Tax Expense
-
EBITDA
-314000
Operating Margin
-8.672225058136238
Total Other Income Expense Net
-786000
Cash
24948000
Short Term Investments
-
Receivables
17983000
Inventories
11818000
Total Current Assets
56387000
Property Plant Equipment
134000
Total Assets
85191000
Payables
11557000
Short Term Debt
5723000
Long Term Debt
19534000
Total Liabilities
59293000
Equity
25898000
Depreciation
1086000
Change In Working Capital
-3207000
Cash From Operations
-2383000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
7038000
Net Change In Cash
4655000
PE
-
PB
7.4015752382423345
ROE
-8.93891420186887
ROA
-2.71742320198143
FCF
-2383000
Fcf Percent
-0.1351596619590494
Piotroski FScore
0
Health Score
12
Deep Value Investing Score
2.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
2
Growth Investing Score
2
Momentum Investing Score
4.5
Net Net Investing Score
1
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
17631000
Quarters > 0 > income Statement > cost Of Revenue
5755000
Quarters > 0 > income Statement > gross Profit
11876000
Quarters > 0 > income Statement > operating Expenses
13405000
Quarters > 0 > income Statement > operating Income
-1529000
Quarters > 0 > income Statement > interest Expense
937000
Quarters > 0 > income Statement > pretax Income
-2315000
Quarters > 0 > income Statement > net Income
-2315000
Quarters > 0 > income Statement > eps
-0.09275168982360511
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
24959114
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-314000
Quarters > 0 > income Statement > operating Margin
-8.672225058136238
Quarters > 0 > income Statement > total Other Income Expense Net
-786000
Quarters > 0 > balance Sheet > cash
24948000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
17983000
Quarters > 0 > balance Sheet > inventories
11818000
Quarters > 0 > balance Sheet > total Current Assets
56387000
Quarters > 0 > balance Sheet > property Plant Equipment
134000
Quarters > 0 > balance Sheet > total Assets
85191000
Quarters > 0 > balance Sheet > payables
11557000
Quarters > 0 > balance Sheet > short Term Debt
5723000
Quarters > 0 > balance Sheet > long Term Debt
19534000
Quarters > 0 > balance Sheet > total Liabilities
59293000
Quarters > 0 > balance Sheet > equity
25898000
Quarters > 0 > cash Flow > net Income
-2315000
Quarters > 0 > cash Flow > depreciation
1086000
Quarters > 0 > cash Flow > change In Working Capital
-3207000
Quarters > 0 > cash Flow > cash From Operations
-2383000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
7038000
Quarters > 0 > cash Flow > net Change In Cash
4655000
Quarters > 0 > ratios > PE
-0.09275168982360511
Quarters > 0 > ratios > PB
7.4015752382423345
Quarters > 0 > ratios > ROE
-8.93891420186887
Quarters > 0 > ratios > ROA
-2.71742320198143
Quarters > 0 > ratios > FCF
-2383000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-0.1351596619590494
Quarters > 0 > health Score
12
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
15009000
Quarters > 1 > income Statement > cost Of Revenue
6003000
Quarters > 1 > income Statement > gross Profit
9006000
Quarters > 1 > income Statement > operating Expenses
11882000
Quarters > 1 > income Statement > operating Income
-2876000
Quarters > 1 > income Statement > interest Expense
937000
Quarters > 1 > income Statement > pretax Income
-3736000
Quarters > 1 > income Statement > net Income
-3796000
Quarters > 1 > income Statement > eps
-0.16298276667625844
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
23290806
Quarters > 1 > income Statement > income Tax Expense
60000
Quarters > 1 > income Statement > EBITDA
-1713000
Quarters > 1 > income Statement > operating Margin
-19.161836231594375
Quarters > 1 > income Statement > total Other Income Expense Net
-860000
Quarters > 1 > balance Sheet > cash
20293000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
15644000
Quarters > 1 > balance Sheet > inventories
12852000
Quarters > 1 > balance Sheet > total Current Assets
51268000
Quarters > 1 > balance Sheet > property Plant Equipment
156000
Quarters > 1 > balance Sheet > total Assets
81158000
Quarters > 1 > balance Sheet > payables
12754000
Quarters > 1 > balance Sheet > short Term Debt
3846000
Quarters > 1 > balance Sheet > long Term Debt
21362000
Quarters > 1 > balance Sheet > total Liabilities
61912000
Quarters > 1 > balance Sheet > equity
19246000
Quarters > 1 > cash Flow > net Income
-3796000
Quarters > 1 > cash Flow > depreciation
1086000
Quarters > 1 > cash Flow > change In Working Capital
749000
Quarters > 1 > cash Flow > cash From Operations
-942000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
165000
Quarters > 1 > cash Flow > net Change In Cash
-777000
Quarters > 1 > ratios > PE
-0.16298276667625844
Quarters > 1 > ratios > PB
9.294055392289307
Quarters > 1 > ratios > ROE
-19.72357892549101
Quarters > 1 > ratios > ROA
-4.6772961383967075
Quarters > 1 > ratios > FCF
-942000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.06276234259444334
Quarters > 1 > health Score
9
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
13139000
Quarters > 2 > income Statement > cost Of Revenue
4790000
Quarters > 2 > income Statement > gross Profit
8349000
Quarters > 2 > income Statement > operating Expenses
11673000
Quarters > 2 > income Statement > operating Income
-3324000
Quarters > 2 > income Statement > interest Expense
891000
Quarters > 2 > income Statement > pretax Income
-4073000
Quarters > 2 > income Statement > net Income
-4073000
Quarters > 2 > income Statement > eps
-0.18013324464509373
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
22611040
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-2096000
Quarters > 2 > income Statement > operating Margin
-25.298728974807823
Quarters > 2 > income Statement > total Other Income Expense Net
-749000
Quarters > 2 > balance Sheet > cash
21070000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
18025000
Quarters > 2 > balance Sheet > inventories
12496000
Quarters > 2 > balance Sheet > total Current Assets
53986000
Quarters > 2 > balance Sheet > property Plant Equipment
178000
Quarters > 2 > balance Sheet > total Assets
84962000
Quarters > 2 > balance Sheet > payables
14404000
Quarters > 2 > balance Sheet > short Term Debt
1968000
Quarters > 2 > balance Sheet > long Term Debt
23105000
Quarters > 2 > balance Sheet > total Liabilities
63421000
Quarters > 2 > balance Sheet > equity
21541000
Quarters > 2 > cash Flow > net Income
-4073000
Quarters > 2 > cash Flow > depreciation
1086000
Quarters > 2 > cash Flow > change In Working Capital
-1464000
Quarters > 2 > cash Flow > cash From Operations
-2832000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
3597000
Quarters > 2 > cash Flow > net Change In Cash
765000
Quarters > 2 > ratios > PE
-0.18013324464509373
Quarters > 2 > ratios > PB
8.061500728842672
Quarters > 2 > ratios > ROE
-18.90812868483357
Quarters > 2 > ratios > ROA
-4.793907864692451
Quarters > 2 > ratios > FCF
-2832000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.21554151761930132
Quarters > 2 > health Score
13
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
13620000
Quarters > 3 > income Statement > cost Of Revenue
2237000
Quarters > 3 > income Statement > gross Profit
11383000
Quarters > 3 > income Statement > operating Expenses
9149000
Quarters > 3 > income Statement > operating Income
2234000
Quarters > 3 > income Statement > interest Expense
831000
Quarters > 3 > income Statement > pretax Income
1582000
Quarters > 3 > income Statement > net Income
1521000
Quarters > 3 > income Statement > eps
0.06865698186435529
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
22153610
Quarters > 3 > income Statement > income Tax Expense
61000
Quarters > 3 > income Statement > EBITDA
3416000
Quarters > 3 > income Statement > operating Margin
16.40234948604993
Quarters > 3 > income Statement > total Other Income Expense Net
-652000
Quarters > 3 > balance Sheet > cash
20305000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
10231000
Quarters > 3 > balance Sheet > inventories
14431000
Quarters > 3 > balance Sheet > total Current Assets
48179000
Quarters > 3 > balance Sheet > property Plant Equipment
199000
Quarters > 3 > balance Sheet > total Assets
80241000
Quarters > 3 > balance Sheet > payables
16050000
Quarters > 3 > balance Sheet > short Term Debt
708000
Quarters > 3 > balance Sheet > long Term Debt
24879000
Quarters > 3 > balance Sheet > total Liabilities
60172000
Quarters > 3 > balance Sheet > equity
20069000
Quarters > 3 > cash Flow > net Income
1521000
Quarters > 3 > cash Flow > depreciation
1003000
Quarters > 3 > cash Flow > change In Working Capital
-1464000
Quarters > 3 > cash Flow > cash From Operations
2225000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-15000000
Quarters > 3 > cash Flow > cash From Financing
10619000
Quarters > 3 > cash Flow > net Change In Cash
-2156000
Quarters > 3 > ratios > PE
0.06865698186435529
Quarters > 3 > ratios > PB
8.477738043749065
Quarters > 3 > ratios > ROE
7.5788529572973244
Quarters > 3 > ratios > ROA
1.8955396866938348
Quarters > 3 > ratios > FCF
2225000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.1633627019089574
Quarters > 3 > health Score
51
Valuation > metrics > PE
-0.09275168982360511
Valuation > metrics > PB
7.4015752382423345
Valuation > final Score
20
Valuation > verdict
146.7% Overvalued
Profitability > metrics > ROE
-8.93891420186887
Profitability > metrics > ROA
-4.105556245233831
Profitability > metrics > Net Margin
-0.131302818898531
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.2894818132674337
Risk > metrics > Interest Coverage
-1.631803628601921
Risk > final Score
11
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.263136574074074
Liquidity > metrics > Quick Ratio
2.579224537037037
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
40
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
41
Prev Risks > 0
-6
Prev Risks > 1
3
Prev Risks > 2
29
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:35:03.161Z
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AJourney Medical Corporation Reports Positive Phase 1 Trial Results for Emrosi, Meeting All Primary Objectives with No Safety Issues Quiver Quantitative
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$13.5
Analyst Picks
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 31.72% of the total shares of Journey Medical Corp
1.
TANG CAPITAL MANAGEMENT LLC(7.0491%)
since
2025/06/30
2.
Wasatch Advisors LP(4.3788%)
since
2025/06/30
3.
Vanguard Group Inc(2.1474%)
since
2025/06/30
4.
BlackRock Inc(2.069%)
since
2025/06/30
5.
Wasatch Micro Cap Value(1.9792%)
since
2025/06/30
6.
Wasatch Micro Cap Value Composite(1.6069%)
since
2025/03/31
7.
Geode Capital Management, LLC(0.9972%)
since
2025/06/30
8.
Vanguard Total Stock Mkt Idx Inv(0.9607%)
since
2025/07/31
9.
Renaissance Technologies Corp(0.9255%)
since
2025/06/30
10.
Essex Investment Management Company, LLC(0.8674%)
since
2025/06/30
11.
iShares Russell 2000 ETF(0.8041%)
since
2025/08/31
12.
American Financial Group Inc(0.6842%)
since
2025/06/30
13.
UBS Group AG(0.6034%)
since
2025/06/30
14.
Vanguard Institutional Extnd Mkt Idx Tr(0.549%)
since
2025/07/31
15.
Fidelity Small Cap Index(0.4681%)
since
2025/06/30
16.
State Street Corp(0.437%)
since
2025/06/30
17.
iShares Russell 2000 Growth ETF(0.4166%)
since
2025/08/31
18.
IMC US Ultra Micro Cap(0.3859%)
since
2025/07/31
19.
The Informed Momentum Company (formerly EAM Investors)(0.3613%)
since
2025/06/30
20.
Opaleye Management Inc(0.3611%)
since
2025/06/30
21.
Northern Trust Corp(0.323%)
since
2025/06/30
22.
Pleiades Small Cap Equity A(0.3173%)
since
2025/06/30
23.
1290 Essex Small Cap Growth I(0.2952%)
since
2025/07/31
24.
Envestnet Asset Management Inc(0.266%)
since
2025/06/30
25.
Legato Capital Management LLC(0.2586%)
since
2025/06/30
26.
Geneos Wealth Management Inc(0.2405%)
since
2025/06/30
27.
Fidelity Extended Market Index(0.2375%)
since
2025/07/31
28.
Vanguard Russell 2000 ETF(0.2184%)
since
2025/07/31
29.
Integrated Wealth Concepts LLC(0.2104%)
since
2025/06/30
30.
Morgan Stanley - Brokerage Accounts(0.1973%)
since
2025/06/30
31.
State St Russell Sm Cap® Indx SL Cl I(0.1615%)
since
2025/08/31
32.
Atria Investments LLC(0.1413%)
since
2025/06/30
33.
Gladstone Institutional Advisory LLC(0.1249%)
since
2025/06/30
34.
Schwab Small Cap Index(0.1157%)
since
2025/07/31
35.
NT R2000 Index Fund - NL(0.1115%)
since
2025/06/30
36.
iShares Micro-Cap ETF(0.1063%)
since
2025/08/31
37.
Fidelity Total Market Index(0.09%)
since
2025/07/31
38.
NT R2000 Index Fund - DC - NL - 3(0.0889%)
since
2025/06/30
39.
Fidelity Series Total Market Index(0.0826%)
since
2025/07/31
40.
iShares Russell 2000 Small-Cap Idx Instl(0.0799%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.